| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $12.0M | -2.5% | -9.8% |
| SG&A Expense | $7.3M | +2.0% | +13.8% |
| Operating Income | -$19.4M | +0.8% | +2.1% |
| Net Income | -$17.6M | +0.4% | +4.6% |
| EPS (Basic) | -$0.65 | +0.0% | -38.3% |
| EPS (Diluted) | -$0.65 | +0.0% | -38.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $37.9M | -9.4% | +0.1% |
| Short-term Investments | $119.4M | -6.0% | +99.0% |
| Current Assets | $161.0M | -6.8% | +57.0% |
| Total Assets | $165.7M | -7.1% | +52.8% |
| Current Liabilities | $13.4M | +2.5% | +29.1% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$76.1M | — | — |
| Capital Expenditures | $83K | — | — |
| Investing Cash Flow | -$55.9M | — | — |
| Financing Cash Flow | $197K | — | — |
| Free Cash Flow | -$76.2M | — | — |
| $13.8M |
| -1.7% |
| +6.2% |
| Stockholders' Equity | $152.0M | -7.6% | +59.1% |